Sign Up
Stories
Boehringer Expands with 500M Euro Investment
Share
Biopharma Companies Announce Public Offe...
Growing Markets for Pain Relief
Infectious Diseases Collaboration Insigh...
Acquisition Progress Amid Safety Concern
AscellaHealth Forecasts Robust Outlook f...
BMY Expands Portfolio with RayzeBio Acqu...
Overview
API
Boehringer Ingelheim, a German pharmaceutical company, is investing 500 million euros in China to boost manufacturing and research.
Ask a question
How could this move influence the dynamics of the pharmaceutical industry in China and beyond?
How might this investment impact Boehringer Ingelheim's competitiveness in the global pharma market?
What specific areas of research and development will benefit from this investment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage
hande